Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen — Stella

Recruiting

Back to Acute Myeloid Leukemia, in Relapse trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Russia

RM Gorbacheva Research Institute, Saint Petersburg

Key details

Phase

Safety & dosing

Sponsor

St. Petersburg State Pavlov Medical University

Enrollment target

~88 participants

Started

May 2024

Primary completion

May 2027

Age range

18 Years – 75 Years

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov